MOL 126
Latest Information Update: 08 Sep 1999
At a glance
- Originator Molecumetics
 - Class Antithrombotics
 - Mechanism of Action Thrombin inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Thrombosis
 
Most Recent Events
- 08 Sep 1999 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
 - 29 Jan 1998 Preclinical development for Thrombosis in USA (Unknown route)
 - 29 Sep 1997 New profile